Table 2. Factors associated with serological response in the patients who received 1 dose or 3 doses of benzathine penicillin G at 12 months of follow-up in univariate and multivariate analysis.
| Univariate analysis | Multvariate analysis | |||||
| Responders(n = 406) | non-responders(n = 167) | P-value | Adjusted oddsratio | 95% confidenceinterval | P-value | |
| Age, mean (SD), years | 33.1 (8.0) | 33.2 (7.3) | 0.89 | 1.01 | 0.99–1.03 | 0.55 |
| Risk, n (%) | ||||||
| MSM | 386 (95.1) | 153 (91.6) | 0.118 | 1.67 | 0.82–2.89 | 0.19 |
| non–MSM | 20 (4.9) | 14 (8.4) | 1 | – | – | |
| Syphilis stage, n (%) | ||||||
| Primary | 34 (8.4) | 17 (10.2) | 0.52 | 1 | – | – |
| Secondary | 249 (61.6) | 82 (49.1) | 0.005 | 1.90 | 1.17–3.09 | 0.01 |
| Early latent | 123 (30.3) | 68 (40.7) | 0.014 | 1.04 | 0.70–1.56 | 0.84 |
| RPR titer, median (IQR) | 1∶64 (32, 128) | 1∶64 (32, 128) | ||||
RPR titer  1∶32 |
353 (86.9) | 125 (74.9) | 0.001 | 1.93 | 1.38–2.69 | <0.001 |
| CD4 count, mean (SD), cells/µl | 460 (242) | 449 (249) | 0.61 | |||
| CD4 ≦200, n (%) | 47 (11.6) | 24 (14.3) | 0.49 | 1 | – | – |
| 200<CD4 ≦350, n (%) | 89 (21.9) | 47 (28.1) | 0.16 | 1.05 | 0.54–2.07 | 0.88 |
| CD4>350, n (%) | 270 (66.5) | 96 (57.5) | 0.084 | 1.51 | 0.69–3.51 | 0.30 |
| PVL, mean (SD), log10 copies/ml | 3.07 (1.51) | 2.99 (1.47) | 0.53 | |||
| PVL <400 copies/ml, n (%) | 192 (47.3) | 76 (45.5) | 0.58 | 0.97 | 0.78–1.21 | 0.79 |
| Prior history of syphilis, n (%) | 142 (35.0) | 61 (36.5) | 0.77 | 0.98 | 0.79–1.21 | 0.82 |
| CART, n (%) | 251 (61.8) | 111 (66.5) | 0.29 | 0.75 | 0.47–1.20 | 0.23 |
| 3 doses of penicillin, n (%) | 208 (51.2) | 70 (41.9) | 0.04 | 1.68 | 1.20–2.36 | 0.002 |
Abbreviations: CART, combination antiretroviral therapy; IQR, interquatile range; PVL, plasma HIV RNA load; RPR, rapid plasma reagin; SD, standard deviation.